Filling services help Dalton seal manufacturing deal with Clarity

If there is one thing that's in right now in contract manufacturing, it is filling services. Catalent, Recipharm and Allied Medical Products have shown how in-demand the services are. Now so has Dalton Pharma Services. The Toronto CMO has a manufacturing services agreement with Clarity Pharmaceuticals, providing cGMP chemistry manufacturing, scale up, aseptic fill and finish services and analytical support for the Australian radiopharmaceutical company.

Dalton has a lot to offer, as the service description says, but it was the fill and finish prospect that sealed the deal. "Our expert capabilities in the manufacture of complex chemical products, including conjugation under sterile cGMP conditions and our strength in aseptic filling, solidified the manufacturing agreement," according to Dalton CEO Peter Pekos.

During this month alone, filling services have been at the center of big development news in contract work worldwide. In North Carolina, Catalent opened a new, 3,000-square-foot fill-finish suite, tying into the drug development and supply solutions provider's focus on boosting its work in biologics. Across the Atlantic in France, Swedish CDMO Recipharm invested around €600,000 ($756,000) on a Dara cartridge filling machine to boost output at its Monts facility. Meanwhile, Swiss pharmaceutical supplier Siegfried Holding AG purchased Irvine, CA, CMO Allied Medical Products for $58 million and an itch to get in on Allied's sterile filling success.

Founded in 2010 and headquartered in Sydney, Clarity specializes in the development of clinical tools for PET imaging and companion diagnostics. The cost of its deal with Dalton was undisclosed.

- read the announcement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.